Search

Your search keyword '"Baggerly, Keith A."' showing total 207 results

Search Constraints

Start Over You searched for: Author "Baggerly, Keith A." Remove constraint Author: "Baggerly, Keith A." Publisher american association for cancer research (aacr) Remove constraint Publisher: american association for cancer research (aacr)
207 results on '"Baggerly, Keith A."'

Search Results

2. Supplementary Figure from Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling

3. Data from Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling

6. Supplementary Table from Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling

7. Supplementary Table 5 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4

8. Supplementary Materials from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4

9. Supplementary Figures from Prevalence of Aflatoxin-Associated TP53R249S Mutation in Hepatocellular Carcinoma in Hispanics in South Texas

11. Data from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4

12. Supplementary Table 1 from Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1–Mediated Cell Death in Uterine Cancer

13. Supplementary Table 4 from Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4

15. Supplementary Tables from Prevalence of Aflatoxin-Associated TP53R249S Mutation in Hepatocellular Carcinoma in Hispanics in South Texas

17. Supplementary Table 1-3 and Figures 1-7. from Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1–Mediated Cell Death in Uterine Cancer

18. Supplementary Data from Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1–Mediated Cell Death in Uterine Cancer

20. Figure S1 from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma

21. Supplementary Materials and Methods, Figures 1 - 14, Table 1 from Molecular Biomarkers of Residual Disease after Surgical Debulking of High-Grade Serous Ovarian Cancer

22. AVPC Molecular Signature Supplementary Figures from Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

23. AVPC Molecular Signature Aparicio Supplementary Material from Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

24. Supplementary Figure Legends from Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

26. Figures S1-S10 from Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape

27. AVPC Molecular Signature Supplementary Tables 1-10 from Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

28. Supplementary Figure 4 from Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

29. Supplementary Figure 1 from Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

30. Information of Microarray Data from Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

31. Figures S1-S6; Table S1-S5 from Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer

32. Data from A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

34. Supplementary Figure legends from Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape

35. Supplementary Tables S1-6 and S8 from Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape

36. Supplementary Tables S7 from Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape

37. Supplementary Methods from Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape

38. Supplementary Figure 2 from A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

40. Supplementary information from Targeting Src and Tubulin in Mucinous Ovarian Carcinoma

42. Supplementary Figure 3 from Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

43. Supplementary Figure 2B from Preclinical and Early Clinical Evaluation of the Oral AKT Inhibitor, MK-2206, for the Treatment of Acute Myelogenous Leukemia

44. Supplemental Figure 5 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics

45. Supplementary Table 3 from From Mice to Humans

46. Supplemental Figure 8 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics

47. Supplementary Table 2 from From Mice to Humans

48. Conflict of Interest Form 1 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics

49. Supplemental Table 5 from Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics

50. Data from From Mice to Humans

Catalog

Books, media, physical & digital resources